Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
4
57%
Ph phase_1
2
29%
Ph phase_2
1
14%

Phase Distribution

2

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 34 (57.1%)

Trials by Status

terminated114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

NCT02531126
terminatedphase_3

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
completedphase_3

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

NCT02576717
completedphase_3

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

NCT02435992
completedphase_2

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02531113
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02531126Phase 3

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Completed
NCT04140305Phase 3

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Terminated
NCT02576717Phase 3

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Completed
NCT02435992Phase 3

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Completed
NCT02531113Phase 2

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Completed
NCT02797015Phase 1

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Completed
NCT02994381Phase 1

A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7